Gain Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview

Gain Therapeutics

19/03/2024 11:07

* Gain Therapeutics Inc  GANX.OQ   GANX.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 21
(estimated) for the period ending December 31 2023
    * The Bethesda Maryland-based  company is expected to report
revenue of $325 thousand, according to the mean estimate from 4
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Gain Therapeutics Inc is
for a
loss of 32 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Gain
Therapeutics
Inc is $9.00​, above​ its last closing price of $4.36. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.45       -0.45      -0.37     Beat    17
 Jun. 30 2023  -0.32       -0.31      -0.62     Missed  -101.6
 Mar. 31 2023  -0.40       -0.39      -0.43     Missed  -9.3​
 Dec. 31 2022  -0.38       -0.38      -0.39     Missed  -3.3
 ​​Sep.        -0.46       -0.46      -0.38     Beat    17.4
 30 2022                                                
 Jun. 30 2022  -0.31       -0.31      -0.43     Missed  -37.2​
 Mar. 31 2022  -0.37       -0.37      -0.28     Beat    23.8
 Dec. 31 2021              -0.49      -0.32     Beat    34.2
 This summary was machine generated March 19 at 11:07 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)